181 related articles for article (PubMed ID: 34477513)
1. Assessment of Combination Approaches of Phytoconstituents with Chemotherapy for the Treatment of Breast Cancer: A Systematic Review.
Sartaj A; Baboota S; Ali J
Curr Pharm Des; 2021; 27(45):4630-4648. PubMed ID: 34477513
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer.
Sartaj A; Baboota S; Ali J
Curr Cancer Drug Targets; 2020; 20(8):603-615. PubMed ID: 32228423
[TBL] [Abstract][Full Text] [Related]
3. Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations.
Sartaj A; Qamar Z; Qizilbash FF; Annu ; Md S; Alhakamy NA; Baboota S; Ali J
Polymers (Basel); 2021 Dec; 13(24):. PubMed ID: 34960948
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Promising Potential of High Permeation Vesicle-Mediated Localized Transdermal Delivery of Docetaxel in Breast Cancer To Overcome the Limitations of Systemic Chemotherapy.
Bathara M; Date T; Chaudhari D; Ghadi R; Kuche K; Jain S
Mol Pharm; 2020 Jul; 17(7):2473-2486. PubMed ID: 32496783
[TBL] [Abstract][Full Text] [Related]
5. Green Approaches for Cancers Management: An Effective Tool for Health Care.
Gupta J; Ahuja A; Gupta R
Anticancer Agents Med Chem; 2022; 22(1):101-114. PubMed ID: 33463475
[TBL] [Abstract][Full Text] [Related]
6. Research Progress in Flavonoids as Potential Anticancer Drug Including Synergy with Other Approaches.
Hussain Y; Luqman S; Meena A
Curr Top Med Chem; 2020; 20(20):1791-1809. PubMed ID: 32357817
[TBL] [Abstract][Full Text] [Related]
7. A Concise Review on Natural Products and Their Derivatives for Breast Cancer Treatment.
Gupta N; Kumar H; Gupta S; S M B; Saini K
Chem Biodivers; 2023 Aug; 20(8):e202300688. PubMed ID: 37431959
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer.
Farghadani R; Naidu R
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216255
[TBL] [Abstract][Full Text] [Related]
10. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
11. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
13. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
16. Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer.
Kaur K; Jaitak V
Anticancer Agents Med Chem; 2019; 19(8):962-983. PubMed ID: 30864529
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.
Blank PR; Dedes KJ; Szucs TD
Pharmacoeconomics; 2010; 28(8):629-47. PubMed ID: 20524722
[TBL] [Abstract][Full Text] [Related]
18. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
